Loading stock data…
Alamar Biosciences, Inc. (ALMR)
$30.80+0.23 (+0.75%)
Pre-Market$31.00+0.20 (+0.65%)· Last close Sep 4
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $26.04M↑ | $13.09M |
| Gross Profit | $14.46M↑ | $6.39M |
| Operating Income | -$12.35M↓ | -$8.55M |
| Net Income | -$21.32M↓ | -$7.66M |
Peer Comparison
JNJUNHPFE
Fundamentals
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.40B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
16.28%
Volume
Today's trading volume
142,949
Recent News
Alamar Biosciences (ALMR) Q2 2026 Earnings Call Transcript
Revenue surged 82% year-over-year to $29.4 million.
Alamar Biosciences Inc (ALMR) (Q2 2026) Earnings Call Highlights: Revenue Surges 82% on 147% ...
Record 60% gross margin and expanded ADDI partnership position the company for 59% annual growth, despite widening net losses and near-term margin fluctuations.
Alamar Biosciences (ALMR) Stock Trades At A Premium To Its Sales
Alamar Biosciences stock has gained 27.2% year to date, yet the company currently screens as expensive on Simply Wall St's broader valuation checks. That mix of strong recent returns and a low value score raises questions about how much optimism is already reflected in the share price. The 27.2% gain year to date suggests investors have been willing to pay up for Alamar Biosciences, and that recent enthusiasm is now central to the valuation story. Upcoming financial results and new product...
Alamar Biosciences Q2 Earnings Call Highlights
Alamar Biosciences (NASDAQ:ALMR) reported second-quarter 2026 revenue of $29.4 million, up 82% from $16.2 million a year earlier, as growth in consumables, instrument placements and service revenue supported the company’s first earnings call since completing its April initial public offering. Chief
Attovia adds to biotech IPO momentum with $289M offering
The startup is the 12th drug company to bank at least $250 million in an IPO this year, nearly matching totals last seen during the sector’s pandemic peak, according to BioPharma Dive data.